# Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

> **NCT07082439** · PHASE2 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 27 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma Metastatic in the Liver

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Odetiglucan

## Key facts

- **NCT ID:** NCT07082439
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-09
- **Final completion:** 2029-09
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082439, "Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT07082439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*